Monte Rosa Therapeutics, Inc.

GLUE · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Market Cap$512,936$290,393$359,400$950,264
- Cash$224,254$128,101$54,912$346,071
+ Debt$42,715$46,039$47,001$0
Enterprise Value$331,397$208,331$351,489$604,193
Revenue$75,622$0$0$0
% Growth
Gross Profit$67,501-$6,222$0$0
% Margin89.3%
EBITDA-$72,991-$137,089-$108,639-$70,750
% Margin-96.5%
Net Income-$72,700-$135,352-$108,501-$73,958
% Margin-96.1%
EPS Diluted-0.98-2.63-2.3-1.59
% Growth62.7%-14.3%-44.7%
Operating Cash Flow$41,996-$43,802-$92,466-$59,363
Capital Expenditures-$3,988-$19,041-$12,911-$9,732
Free Cash Flow$38,008-$62,843-$105,377-$69,095
Monte Rosa Therapeutics, Inc. (GLUE) Financial Statements & Key Stats | AlphaPilot